Page 11 - Patrick Lu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Hits: 137 GAITHERSBURG, MD, USA and GUANGZHOU, China I April 21, 2021 I RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today execution of definitive agreements for a seed round financing of $10 million. RNAimmune is a spin-off entity from Sirnaomics, a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases. Smooth River and Hong Kong Hongrun led the investment, with participation from Shanghai Walga Biotechnology, High Forest Inve...

Sirnaomics Initiates Phase 2 Study Using STP705 for Keloid Scar Prevention Company Expects to Report Interim Clinical Data in the Second Half of 2021 News provided by Share this article Share this article GAITHERSBURG, Md. and SUZHOU BIOBAY, China, April 18, 2021 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced the initiation of a Phase 2 study of the company's lead drug candidate, STP705, for Keloid scar prevention. The Phase 2, multi-center, randomized, double-bl...

3 months ago Playfull is Named an Official Partner of CLG NEW YORK–(BUSINESS WIRE)–CLG, a top-tier North American esports organization, and Playfull, a premier rewards platform for gamers, today announced a marketing partnership that names Playfull an Official Partner of CLG. The partnership includes marquee brand integration for Playfull across CLG’s digital channels and website. “CLG is always looking for unique opportunities to engage our fanbase and we believe this partnership allows us to connect with CLG fans and the esports community,” said Dan...

/PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic...

Search jobs 20-Dec-2020 Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer GAITHERSBURG, Md. and SUZHOU BIOBAY, China, Dec. 20, 2020 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced positive efficacy and safety results from a Phase 2a clinical study of the company's lead drug candidate, STP705, for treatment of squamous cell skin cancer. The open label, dose escalati...